XmAb 5871

Drug Profile

XmAb 5871

Alternative Names: AMG 729; Anti-CD19 monoclonal antibody - Xencor; XmAb® 5871

Latest Information Update: 16 Nov 2016

Price : $50

At a glance

  • Originator Xencor
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; Fc gamma receptor IIB modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 13 Nov 2016 Efficacy and adverse events data from the XmAb5871-03 phase II trial in Autoimmune disorders (IgG4-Related disease) released by Xencor
  • 01 Jul 2016 Phase-I clinical trials in Autoimmune disorders in USA (SC) , NCT02867098)
  • 07 Mar 2016 Phase-II clinical trials in Autoimmune disorders in USA (IgG4-Related disease) (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top